AKUMS

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS

BSE: 544222

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

647.35-3.3 (-0.50%)

8 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

93.4 / 100

Value Score

53.5 / 100

Price Momentum Score

88.3 / 100

QVM Score

96.5 / 100

Key Metrics

Market Cap

9911.06

P/E (TTM)

38.84

P/B

2.99

P/S (TTM)

2.27

EV/EBITDA

16.01

CAPE (5Y)

111.61

ROE (TTM)

8.02

ROCE (TTM)

11.07

ROA (TTM)

5.34

Avg 3Y ROE

8.49

Earnings 3Y CAGR

40.37

Sales 3Y CAGR

6.05

Sales 5Y CAGR

9.87

Debt/Equity

0.05

Consensus TP

680.00

Strong Buy %

66.67

Promoter Holding

75.26

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Akums Drugs & Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 88.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

88.3 / 100

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.05 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.02 in the last 1 year

What is Debt to Equity?

Company's earnings are of high quality

Earnings quality score of 90.5 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

90.5 / 100

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 38.84 indicates that the stock is expensive on a standalone basis and is at a 27.89% premium to industry median P/E

What is P/E Ratio?

Median: 30.37

Value 38.84

-215.443255.34

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -1.72% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Not enough data

Low and declining ROE

The company reported low ROE of 8.02% for 12-month ended 31 Mar 2026 and ROE declined by -997 bps from 1 year ago

What is ROE (FY)?

Low but stable operating margin

The company reported low operating margin of 8.43% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 95 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 5.85% for 12-month ended 31 Mar 2026 and the growth was 5.39 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 5.85

-82.35114662

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -26.25% for 12-month ended 31 Mar 2026 and the growth was 34.37 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Akums Drugs & Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Akums Drugs & Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Akums Drugs & Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2013	Aug 2013	Sep 2014	Sep 2015	Sep 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	0.00	0.00	0.00	99.63	100.00	100.00	100.00	100.00	84.91	84.91	84.91	84.91	75.26	75.26	75.26	75.26	75.26	75.26	75.26
Indian Promoter	0.00	0.00	0.00	99.63	100.00	100.00	100.00	100.00	84.91	84.91	84.91	84.91	75.26	75.26	75.26	75.26	75.26	75.26	75.26
Foreign Promoter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	14.58	13.08	13.17	13.09	11.56	15.55	15.72
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	5.18	5.54	6.11	6.73	6.44	11.23	10.95
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.72	0.67	0.66	0.61	0.63	0.65	0.60
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.34	6.36	5.77	4.24	2.27	1.14	1.38
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.50	0.62	1.51	2.21	2.53	2.81
Non-Institution	100.00	100.00	100.00	0.37	0.00	0.00	0.00	0.00	15.09	15.09	15.09	15.09	10.16	11.66	11.58	11.66	13.19	9.19	9.02
Bodies Corporate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.09	15.09	0.00	-	0.22	0.48	0.55	0.36	0.43	0.50	0.50
Others (incl. Retail) No. of shareholders	100.00 9	100.00 9	100.00 9	0.37 7	0.00 0	0.00 0	0.00 0	0.00 0	0.00 0	0.00 0	15.09 1	15.09 1	9.94 57,343	11.18 68,152	11.03 69,086	11.30 69,115	12.76 75,077	8.69 76,562	8.52 72,288

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.22%	183 / 250
2	Nifty Total Market	0.01%	678 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Akums Drugs & Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
ICICI PRUDENTIAL MUTUAL FUND	22 Dec 2025	buy	₹ 428.00	72.79 lac	₹ 311.52 cr
RUBY QC INVESTMENT HOLDINGS PTE.LTD.	22 Dec 2025	sell	₹ 428.00	72.79 lac	₹ 311.52 cr

Corporate Actions

History of Akums Drugs & Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 1/share
Record date: 3rd Jul 2026Ex-date: 3rd Jul 2026
Announced on: 14th May 2026
Dividend₹ 2/share
Record date: 3rd Jul 2026Ex-date: 3rd Jul 2026
Announced on: 14th May 2026

Company Profile

Overview of Akums Drugs & Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Opera...

Key personnel

Mr. Sumeet Sood

Chief Financial Officer

Mr. Dharamvir Malik

Compliance Officer, Company Secretary

Sandeep JainD

Managing Director and Co-Founder, Executive Director

Mr. Sanjeev JainD

Managing Director and Co-Founder, Executive Director

Mr. Sanjay Kumar SinhaD

Whole Time Director, President - Operations

Mr. Sunil Kumar ThakurD

Non-Executive Non-Independent Director

Ms. Matangi GowrishankarD

Independent Director

Mr. Kewal Kundanlal HandaD

Independent Director

View all

Incorporated on

19 Apr 2004

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

7,337

IPO date

06 Aug 2024

Free Float

3,03,54,648

Website

https://www.akums.in/

Phone no.

+911147511000

Address

Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I (adjoining CBSE Office), DELHI, 110083, India

Frequently Asked Questions

What is the current share price of Akums Drugs & Pharmaceuticals Ltd.?

The current share price of Akums Drugs & Pharmaceuticals Ltd. is ₹ 647.35 as of 8 Jul 2026.

What is the market capitalisation of Akums Drugs & Pharmaceuticals Ltd.?

The market capitalisation of Akums Drugs & Pharmaceuticals Ltd. stands at ₹ 9,911.06 Cr.

What is the PE ratio of Akums Drugs & Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Akums Drugs & Pharmaceuticals Ltd. is 38.84 as of the latest trailing twelve months data.

What is the ROE and ROCE of Akums Drugs & Pharmaceuticals Ltd.?

Akums Drugs & Pharmaceuticals Ltd. has a Return on Equity (ROE) of 8.02% and a Return on Capital Employed (ROCE) of 11.07% as per the latest financial reports.

What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd.?

The 52-week high of Akums Drugs & Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Akums Drugs & Pharmaceuticals Ltd.?

The dividend yield of Akums Drugs & Pharmaceuticals Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Akums Drugs & Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 1.38%, Domestic Institutional Investors (DII) hold 11.55% and retail/public investors hold 8.52% of Akums Drugs & Pharmaceuticals Ltd. shares.

What sector does Akums Drugs & Pharmaceuticals Ltd. belong to?

Akums Drugs & Pharmaceuticals Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Akums Drugs & Pharmaceuticals Ltd. with a consensus target price of ₹ 680.00, implying 5.04% upside from current levels.

What is the beta of Akums Drugs & Pharmaceuticals Ltd.?

The beta of Akums Drugs & Pharmaceuticals Ltd. is 0.99, indicating its price volatility relative to the broader market. Over the past 1 year, Akums Drugs & Pharmaceuticals Ltd. has delivered an absolute return of 10.58%.

What is the RSI of Akums Drugs & Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Akums Drugs & Pharmaceuticals Ltd. is 68.39, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Akums Drugs & Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Akums Drugs & Pharmaceuticals Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Company Profile

Corporate Actions

Stock Analysis

Holdings and Presence